Hemispherx Biopharma Price: 0.37
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HEB Price Rankings
| Overall | 0th percentile | 6861 of 6902 |
| Sector | 1st percentile | 559 of 567 in Healthcare |
| Industry | 2nd percentile | 179 of 183 in Biotechnology |
HEB Price Range, Past 5 Years
| Minimum | 0.80 | Sep 27 2002 |
| Maximum | 17.88 | Mar 9 2000 |
| Average | 3.98 |
About Price
The price of one share of stock, which is set by the market. Share price can be used to find a company's total market value, as represented by market capitalization.
Learn More
You may also be interested in these HEB related companies
HEB News
$HEB , I am early but bot it this morning. loking for a nice pop
about 9 days ago by 3DTRADINGTRADER
about 9 days ago by 3DTRADINGTRADER
UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico
Jan 23, 11:00AM Benzinga
Jan 23, 11:00AM Benzinga
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
Jan 17, 8:30AM GlobeNewswire
Jan 17, 8:30AM GlobeNewswire
Hemispherx Biopharma (HEB) Recieves FDA Extension for NDA for Treatment of Chronic Fatigue Syndrome
Jan 11, 8:35AM Street Insider
Jan 11, 8:35AM Street Insider
$HEB shares up 14% following extension to modify NDA for treatment of CFS
about 32 days ago by Street_Insider
about 32 days ago by Street_Insider
Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification
Jan 11, 8:31AM Street Insider
Jan 11, 8:31AM Street Insider
FDA Grants $HEB Extension in Its Pending New Drug Application for the Treatment of Chronic Fatigue
about 32 days ago by Benzinga
about 32 days ago by Benzinga
What's up with $HEB !?!? Up 20% on more than 4X average daily volume.
about 68 days ago by swingtrades99
about 68 days ago by swingtrades99
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
Nov 09, 4:13PM GlobeNewswire
Nov 09, 4:13PM GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
Nov 09, 12:26PM GlobeNewswire
Nov 09, 12:26PM GlobeNewswire
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
Oct 24, 10:22AM GlobeNewswire
Oct 24, 10:22AM GlobeNewswire
Hemispherx Biopharma to Present at the Rodman and Renshaw 13th Annual Global Investment Conference
Sep 08, 4:30PM GlobeNewswire
Sep 08, 4:30PM GlobeNewswire
Hemispherx (HEB) Enters New Alferon N Injection Agreement with Armada Health Care
Sep 06, 8:40AM Street Insider
Sep 06, 8:40AM Street Insider
Hemispherx Biopharma Enters Into a Strategic Alliance With Armada Health Care for Alferon N Injection(R)
Sep 06, 8:30AM GlobeNewswire
Sep 06, 8:30AM GlobeNewswire
FDA authorizes new Hemispherx $HEB clinical trial of intranasal Ampligen(R); stock moving in pre-market
about 207 days ago by Street_Insider
about 207 days ago by Street_Insider
Hemispherx Biopharma Says FDA Lifts Hold On phase 2 Alferon Trial $heb
about 404 days ago by goldenchris
about 404 days ago by goldenchris
El CEO de $MCP me hace acordar al CEO delincuente de $HEB asi terminara.
about 408 days ago by sebatrader
about 408 days ago by sebatrader
Manuel Asensio has numerous SEC violations & should've stuck to SS: & reporting on Small Cap shams like $HEB. His $NFLX remarks = no value.
about 436 days ago by Legacy_Trades
about 436 days ago by Legacy_Trades
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.37 | 0.04 | 10.45% | 50.13M |
| AGM | 20.40 | -0.54 | -2.58% | 211.14M |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| CVS | 43.18 | 0.18 | 0.42% | 56.20B |
| FLR | 59.57 | -0.65 | -1.08% | 10.35B |
| XIN | 2.36 | -0.08 | -3.28% | 180.54M |
| ANR | 21.04 | -1.36 | -6.07% | 4.76B |
| CBI | 43.42 | -0.23 | -0.53% | 4.28B |
| WFT | 17.79 | -0.41 | -2.25% | 13.33B |
